Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

- Diagnosis of moderate to severe Crohn's Disease confirmed by endoscopy or radiologic evaluation for greater than 4 months (16 weeks) - Inadequate response to conventional therapy for Crohn's Disease - Subjects >=18 and <=75 years of age and in good health (Investigator discretion) with a recent stable medical history - Harvey Bradshaw Index score of 7 or higher

- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study - Female subject who is pregnant or breast-feeding or considering becoming pregnant - Previous treatment with adalimumab or previous participation in an adalimumab clinical study - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Subjects with any prior exposure to Tysabri® (natalizumab) - Subjects on prednisone >40 mg/day (or equivalent), subjects on budesonide >9 mg/day, or subjects who are taking prednisone and budesonide concurrently at Baseline